MX2016007865A - Peptidos citotoxicos y conjugados de los mismos. - Google Patents

Peptidos citotoxicos y conjugados de los mismos.

Info

Publication number
MX2016007865A
MX2016007865A MX2016007865A MX2016007865A MX2016007865A MX 2016007865 A MX2016007865 A MX 2016007865A MX 2016007865 A MX2016007865 A MX 2016007865A MX 2016007865 A MX2016007865 A MX 2016007865A MX 2016007865 A MX2016007865 A MX 2016007865A
Authority
MX
Mexico
Prior art keywords
immunoconjugates
peptides
compositions
conjugates
formula
Prior art date
Application number
MX2016007865A
Other languages
English (en)
Inventor
Wang Xing
Uno Tetsuo
Jin Yunho
Grunewald Jan
Ou Weijia
Geierstanger Bernhard
Wan Yongqin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016007865A publication Critical patent/MX2016007865A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

En la presente se dan a conocer novedosos péptidos citotóxicos de la fórmula (I) como se describen en la presente: (ver Fórmula) y el uso de estos péptidos en la elaboración de inmunoconjugados (es decir, conjugados de anticuerpo-fármaco). También se describen en la presente inmunoconjugados (es decir, conjugados de anticuerpo-fármaco), los cuales comprenden tales péptidos citotóxicos novedosos enlazados a una fracción de enlace al antígeno, tal como un anticuerpo; en donde estos inmunoconjugados son útiles para el tratamiento de trastornos proliferativos celulares. La invención proporciona además composiciones farmacéuticas que comprenden estos inmunoconjugados, composiciones que comprenden los inmunoconjugados con un co-agente terapéutico, y métodos para usar estos inmunoconjugados y composiciones para el tratamiento de la trastornos de proliferación celular.
MX2016007865A 2013-12-17 2014-12-17 Peptidos citotoxicos y conjugados de los mismos. MX2016007865A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917293P 2013-12-17 2013-12-17
PCT/US2014/070800 WO2015095301A2 (en) 2013-12-17 2014-12-17 Cytotoxic peptides and conjugates thereof

Publications (1)

Publication Number Publication Date
MX2016007865A true MX2016007865A (es) 2017-01-11

Family

ID=52463118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007865A MX2016007865A (es) 2013-12-17 2014-12-17 Peptidos citotoxicos y conjugados de los mismos.

Country Status (16)

Country Link
US (3) US9988420B2 (es)
EP (2) EP3753578A1 (es)
JP (2) JP6636925B2 (es)
KR (1) KR20160098257A (es)
CN (1) CN105899526A (es)
AU (1) AU2014364812B2 (es)
BR (1) BR112016012538A2 (es)
CA (1) CA2930614A1 (es)
EA (1) EA201691251A1 (es)
ES (1) ES2758506T3 (es)
IL (1) IL245558B (es)
MX (1) MX2016007865A (es)
PL (1) PL3082877T3 (es)
PT (1) PT3082877T (es)
SG (1) SG11201604877UA (es)
WO (1) WO2015095301A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150115000A (ko) * 2013-02-08 2015-10-13 아이알엠 엘엘씨 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
CN105358174B (zh) 2013-03-15 2019-03-15 酵活有限公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
US10675355B2 (en) 2013-12-27 2020-06-09 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
AU2014373574B2 (en) 2013-12-27 2020-07-16 Zymeworks Bc Inc. Sulfonamide-containing linkage systems for drug conjugates
EP3129407A2 (en) * 2014-03-12 2017-02-15 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
CN106573956A (zh) * 2014-06-13 2017-04-19 诺华股份有限公司 澳瑞他汀衍生物及其缀合物
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP6987424B2 (ja) 2016-05-11 2022-01-05 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを洗浄および／または消毒する方法
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
UY38265A (es) * 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
EP3883914A4 (en) * 2018-11-23 2022-04-06 Wuxi Biologics Ireland Limited ORTHOPHTHALALDEHYDE-CONTAINING LINKERS AND METHODS FOR PRODUCTION OF ANTIBODY-DRUG CONJUGATE
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
EP4279502A1 (en) * 2021-01-18 2023-11-22 Ajinomoto Co., Inc. Compound or salt thereof, and antibody obtained therefrom
WO2023061405A1 (zh) * 2021-10-12 2023-04-20 成都科岭源医药技术有限公司 一种高稳定性的靶向接头-药物偶联物
WO2024023735A1 (en) * 2022-07-27 2024-02-01 Mediboston Limited Auristatin derivatives and conjugates thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
DE69230824T2 (de) 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
ATE282630T1 (de) 1993-10-01 2004-12-15 Teikoku Hormone Mfg Co Ltd Dolastatin-derivate
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE196913T1 (de) 1995-04-21 2000-10-15 Teikoku Hormone Mfg Co Ltd Neuartige peptidderivate
AU729035B2 (en) 1997-06-12 2001-01-25 Novartis Ag Artificial antibody polypeptides
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
WO2007002222A2 (en) 2005-06-20 2007-01-04 Psma Development Company, Llc Psma antibody-drug conjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
NO2842575T3 (es) 2008-03-18 2018-02-24
JP5933562B2 (ja) 2010-09-29 2016-06-15 シアトル ジェネティックス， インコーポレイテッド Ｎ−カルボキシアルキル−アウリスタチンおよびその使用
CA2815363C (en) 2010-10-22 2020-07-14 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
PL2678037T3 (pl) 2011-02-25 2015-05-29 Lonza Ag Rozgałęziony łącznik do koniugatów białko-lek.
US9029406B2 (en) 2011-03-16 2015-05-12 Seattle Genetics, Inc N-carboxyalkylauristatins and use thereof
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
KR102030856B1 (ko) 2011-05-27 2019-10-10 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
SG11201401452PA (en) 2011-11-17 2014-06-27 Pfizer Cytotoxic peptides and antibody drug conjugates thereof
EP2794653B1 (en) * 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2855520B1 (en) * 2012-06-04 2018-09-26 Novartis AG Site-specific labeling methods and molecules produced thereby
KR20150115000A (ko) * 2013-02-08 2015-10-13 아이알엠 엘엘씨 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위

Also Published As

Publication number Publication date
EP3082877B1 (en) 2019-08-28
BR112016012538A2 (pt) 2017-09-26
US20180244717A1 (en) 2018-08-30
PL3082877T3 (pl) 2020-02-28
JP2017503777A (ja) 2017-02-02
PT3082877T (pt) 2019-12-03
AU2014364812B2 (en) 2017-05-25
US20190382441A1 (en) 2019-12-19
CA2930614A1 (en) 2015-06-25
IL245558B (en) 2020-01-30
EP3082877A2 (en) 2016-10-26
EA201691251A1 (ru) 2016-11-30
SG11201604877UA (en) 2016-07-28
US9988420B2 (en) 2018-06-05
US10787480B2 (en) 2020-09-29
WO2015095301A3 (en) 2015-09-03
ES2758506T3 (es) 2020-05-05
EP3753578A1 (en) 2020-12-23
KR20160098257A (ko) 2016-08-18
AU2014364812A1 (en) 2016-07-07
JP6636925B2 (ja) 2020-01-29
WO2015095301A2 (en) 2015-06-25
US10392421B2 (en) 2019-08-27
IL245558A0 (en) 2016-06-30
CN105899526A (zh) 2016-08-24
JP2020023514A (ja) 2020-02-13
US20160311853A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CY1122161T1 (el) Συζευγμενα αντισωματα anti-cd38
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX352738B (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
PH12019501330A1 (en) Antibody drug conjugates for ablating hematopoietic stem cells
TN2015000396A1 (en) Antibody drug conjugates
UA110370C2 (en) Conjugates of amatoxin with improved linkages
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MX2015011583A (es) Derivados de amatoxina.
NZ734892A (en) Amatoxin-antibody conjugates
MX340090B (es) Analogos de spliceostatina.
PH12016501995A1 (en) Tubulysin derivatives
EA201491441A1 (ru) Композиции конъюгата xten и способы их получения
NZ707086A (en) Anti-cd40 antibodies and methods of use
IN2014CN04961A (es)
MY169147A (en) Drug-protein conjugates
EA201500506A1 (ru) КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16a
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
WO2014172309A3 (en) Therapeutic compositions for neutralizing type i interferons, and methods of use

Legal Events

Date Code Title Description
FG Grant or registration